BPC-157 +TB-500 (Body Protection Compound-157 + Thymosin Beta-4)

A high-purity, peptide-based injectable formulation combining BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment) in a synergistic 1:1 ratio, designed exclusively for laboratory, analytical, and research use. This dual-peptide complex is widely studied for its potential roles in tissue regeneration, angiogenesis, and accelerated recovery across musculoskeletal and soft-tissue models.

The complementary mechanisms of BPC-157 and TB-500 make this formulation ideal for studies investigating cell migration, wound repair, inflammation modulation, and tendon-to-bone healing.

Synergistic regenerative activity:
BPC-157 promotes angiogenesis and fibroblast activity, while TB-500 enhances actin regulation and cellular migration—together supporting accelerated recovery in soft tissue models.

Anti-inflammatory potential:
Both peptides have been studied for modulating inflammatory cytokines and promoting balanced healing responses in preclinical models.

Enhanced vascularization:
TB-500’s role in upregulating VEGF and BPC-157’s angiogenic effects make this combination valuable in studies of blood-flow restoration and ischemic tissue recovery.

Supports tendon, ligament, and muscle research:
Preclinical studies suggest combined effects in promoting tendon-to-bone junction healing and myocyte repair following induced damage.

Ideal for low-dose, sustained studies:
Both peptides demonstrate activity at microgram-level doses, allowing researchers to achieve strong biological responses with minimal administration frequency.

Our BPC-157 + TB-500 (5 mg + 5 mg) blend delivers dual high-purity peptides in a ready-to-reconstitute lyophilized form—trusted for in-vitro and in-vivo research across regenerative biology and inflammation models.

• ≥99% purity verified via HPLC & Mass Spectrometry

• Lyophilized sterile powder for stability and long shelf life

• Endotoxin-screened and filtered for laboratory safety

• Full COA (Certificate of Analysis) available upon request

• Discreet, tracked shipping for laboratory assurance

BPC-157 (a gastric-derived pentadecapeptide) has been shown in preclinical models to accelerate angiogenesis, enhance fibroblast proliferation, and support tendon and ligament healing via nitric-oxide–mediated pathways.

TB-500 (a synthetic fragment of Thymosin Beta-4) promotes cell migration and upregulates actin polymerization, key to cytoskeletal remodeling and wound closure.

When combined, the two peptides demonstrate complementary and potentially synergistic effects across several research domains:

• Tendon, ligament, and muscle repair models

• Angiogenesis and ischemic injury studies

• Inflammation and cytokine modulation research

• Epithelial and endothelial regeneration assays

• Joint degeneration and post-injury recovery studies

Is this combination legal to purchase?
A: Our BPC-157 + TB-500 formulation is sold strictly as a research chemical and not for human consumption. Customers must ensure compliance with local regulations before purchase or use.

How should it be reconstituted for research?
A: Reconstitute each vial with sterile bacteriostatic water to achieve the desired concentration. Store refrigerated (2–8 °C) after reconstitution. Do not freeze once mixed.

How do BPC-157 and TB-500 differ mechanistically?
A: BPC-157 is primarily associated with gastrointestinal-derived growth modulation and angiogenesis, while TB-500 is a thymosin peptide fragment that regulates actin dynamics and cellular migration. Their distinct pathways make them complementary in regenerative models.

What are the primary areas of research interest?
A: Wound healing, angiogenesis, tendon-to-bone interface recovery, muscle micro-tears, and anti-inflammatory signaling. Both peptides are widely studied for their potential to enhance regenerative outcomes in damaged tissue models.

Can they be used separately?
A: Yes.

What if the lyophilized peptide clumps or discolors?
A: Minor clumping is normal and dissolves upon reconstitution. If dark discoloration or particulate matter persists after reconstitution, do not use.

Are there known limitations in research data?
A: Most studies are preclinical. Ongoing research continues to clarify pharmacokinetics, systemic interactions, and dose-response characteristics in mammalian models.

Please check your email after purchase for detailed guides on peptide handling, reconstitution, and reference literature for regenerative biology research.